The gene therapy Zolgensma helped children born with spinal muscular atrophy grow up to run and play. But the cost was stunning: $2M per dose.

While taxpayers and small charities funded the drug’s early development, executives, venture-capital backers and a pharma giant have reaped the profits.

Comments